+255.9%
TXN vs MRNA
+786.4%
-530.5%
-33.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -7.7% | -2.2% | -5.5% | -7.6% |
| 7D | -13.1% | -12.7% | -0.4% | -12.6% |
| 30D | -6.9% | -20.7% | +13.8% | -6.0% |
| 3M | -0.2% | +46.3% | -46.5% | -2.4% |
| 6M | -12.6% | +305.2% | -317.9% | -23.4% |
| YTD | +55.3% | +561.2% | -505.9% | +28.9% |
| 1Y | +75.8% | +772.1% | -696.3% | +41.8% |
| 3Y | +84.0% | +147.0% | -63.0% | +61.3% |
| 5Y | +55.5% | -26.1% | +81.6% | +43.3% |
| All | +255.9% | +786.4% | -530.5% | +189.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling